Kazia Therapeutics Annual Report 2021

KAZIA IS PRIVILEGED TO WORK WITH CANCER RESEARCHERS AROUND THE GLOBE WHO SHARE OUR PASSION FOR GOOD SCIENCE AND OUR COMMITMENT TO PATIENTS. Dr Sabine Mueller Dr Lakshmi Nayak is Director of the Center for CNS Lymphoma at Dana- Farber Cancer Institute in Boston, MA, and an Assistant Professor of Neurology at Harvard Medical School. After completing her residency at Weill Cornell Medical College in New York, she underwent a fellowship at Memorial Sloan Kettering Cancer Center. She became a board-certified neurologist in 2009, and a board- certified neuro-oncologist in 2013. Dr Nayak has been instrumental in establishing Dana-Farber as a centre of excellence for the treatment of primary CNS lymphoma. The CNS Lymphoma Center is the first of its kind dedicated specifically to providing multi-disciplinary care to patients with primary or secondary CNS lymphoma. Her research is focussed on exploring the genomic landscape of CNS lymphomas, including identification of targets and mechanisms of resistance and response to targeted agents. To this end, she has established a cerebrospinal fluid and brain tumour tissue banking protocol and developed patient-derived xenograft models for this rare disease. In addition to her research interests in CNS lymphoma, Dr Nayak has led numerous multicentre clinical trials in glioblastoma and other solid tumours. The US National Cancer Institute‚Äôs Cancer Therapy Evaluation Program (CTEP) selected her proposal for a phase I study of two novel agents for a study in solid tumours, including glioblastoma, from among a highly competitive field. Dr Nayak is an author of more than seventy peer-reviewed academic publications in brain cancer. She is a highly sought-after thought leader in the field, serving on a national panel of the Joint Guidelines Committee of the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) which has drafted guidelines for management of progressive glioblastoma, as well as on the Neuro- Oncology Guidelines Committee for the American Academy of Neurology (AAN). She leads the Neurologic Assessment in Neuro- Oncology (NANO) working group with international thought-leaders in neuro-oncology and has developed an objective and quantifiable measure of neurologic function to facilitate comparison across clinical trials in brain tumours. Dr Nayak has conducted preclinical and clinical research on the PI3K/ mTOR pathway in primary brain tumours and is the principal investigator for a phase II clinical study of paxalisib (NCT04906096) in primary CNS lymphoma, which commenced patient recruitment in June 2021. Dr Sabine Mueller is a paediatric neuro-oncologist who specialises in caring for children with brain tumours and related genetic syndromes. She obtained her PhD and her medical degree from the Universität Hamburg School of Medicine. She is a Professor at University of California, San Francisco (UCSF), Departments of Neurology, Neurosurgery and Pediatrics. In addition to her roles at UCSF, Dr Mueller also serves as the Clinical Lead of The Diffuse Didline Glioma Center of at the Universität- Kinderspital in Zurich, Switzerland. The DIPG/DMG Center in Zurich is a leading multi-disciplinary unit focused on clinical practice and translational research, with a mission to improve the prognosis for children with DIPG/ DMG. Prior to her medical career, Dr Mueller worked as a scientist, director of genomics, and project leader for a brain tumour program at AGY Therapeutics, a biotechnology company in South San Francisco. Dr Mueller is a highly experienced clinical researcher, with specialist qualifications in trial design and methodology. She is the Project lead of the Pacific Pediatric Neuro- Oncology Consortium (PNOC), an international coalition of more than two hundred brain tumour specialists, focused on finding new treatment options for children with brain cancer. Dr Mueller is the principal investigator for an adaptive clinical study which will explore multiple combination therapies in DIPG/DMG. Paxalisib will be one of the therapies under investigation. Recruitment is expected to commence in the second half of calendar 2021. WORKING WITH THE BEST Kazia Therapeutics Limited 14 Annual Report 2021 Dr Lakshmi Nayak